Current stock page

Stock Analysis

ADMA Biologics, Inc. (ADMA) Stock Analysis

ADMA Biologics, Inc. (ADMA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ADMA Stock Analysis Summary

ADMA Biologics, Inc. (ADMA) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Risk is the weakest current factor at 56/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ADMA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$13.68
AIQ Score78/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$3.06B
P/E Ratio (TTM)17.32
Forward P/E—
EPS (Q3 FY2026)$0.22
Revenue (Q3 FY2026)$141.1M
Dividend Yield (TTM)0.00%
Beta-0.09
Volume4.16M
52-week range$7.21-$20.46
RSI 1471.04
50-Day SMA$10.58
200-Day SMA$10.73
Analyst Price Target$18.00
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

ADMAADMA Biologics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$13.68+$0.44 (+3.32%)

Latest quote

  • Momentum
    91
  • Value
    80
  • Quality
    72
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ADMA Stock Analysis Summary

ADMA Biologics, Inc. (ADMA) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Risk resilience is the weakest current factor at 56/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, ADMA has AIQ Score of 78/100 with Momentum base of 91/100 and fading Risk resilience at 56/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (91/100) leads while Risk resilience (56/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 3.32% stock move · ADMA classified in Biotechnology.

Current Evidence

BullishADMA is in a bullish AIQ regime; Momentum is the strongest visible factor at 91/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ADMA Bullish or Bearish Right Now?

ADMA currently has a bullish overall setup. Momentum is the strongest factor at 91/100, while Risk Resilience is weakest at 56/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 72/100.
  • - Momentum is constructive at 91/100.
  • - Price is +29.36% above its 50-day SMA.
  • - Analyst target implies +31.58% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (38 vs 6).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

ADMA's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 2 neutral, and 6 sell votes. ADMA's 14-day RSI is 71.04, which places the stock in an overbought momentum range. ADMA's beta is -0.09, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ADMA?

The largest recent change in ADMA is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+3.0
Quality
+0.0
Risk
+1.0

What Would Change the ADMA Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ADMA Decision Framework

Public evidence layers, setup checks, and risk context for ADMA Biologics, Inc..

ADMA Biologics, Inc. (ADMA) Stock Analysis

ADMA Biologics, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 91/100. Beta is -0.09, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextADMA is in a Bullish AIQ regime with score 78/100.
Signal ConflictThe primary conflict is that momentum leads at 91/100 while risk lags at 56/100.
Factor EvidenceMomentum 91/100 · Value 80/100 · Quality 72/100 · Risk 56/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 91/100.

TimingPass

Momentum is 91/100 and RSI (14) is 71.0.

Regime fitPass

ADMA is in a Bullish regime at 78/100.

Risk controlWait

Risk factor is 56/100 with beta -0.09 and annual volatility 58.93%.

ConflictWait

Current conflict: momentum leads at 91/100 while risk lags at 56/100.

AIQ Score
78/100
Price
$13.68
Beta
-0.09
RSI (14)
71

ADMA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ADMA Fundamentals

ADMA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$141.1M
Net income
$49.88M
Free cash flow
$15.37M
View full ADMA fundamental analysis

ADMA Technical Analysis

ADMA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
71.04
Price vs SMA-50
+29.36%
View full ADMA technical analysis

ADMA Stock Catalysts

Track ADMA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$18.00
News items
2
View ADMA earnings and stock catalysts

ADMA Dividend Analysis

ADMA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ADMA dividend history and analysis

ADMA Financial Data

ADMA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$141.1M
EPS
$0.22
Periods
8
View ADMA financials

ADMA Risk Analysis

ADMA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
-0.09
Risk score
56/100
1Y volatility
58.93%
View ADMA risk analysis

ADMA Stock News

ADMA stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 15, 2026
Sentiment
—
Read ADMA stock news

ADMA vs Biotechnology Peers

Current peer cohort: ADMA · AGIO · ALMS · AMLX · ANAB. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ADMA
Current stock
78/10080/10091/10056/100-0.0158.93%Current
AGIO
Agios Pharmaceuticals, Inc.
56/10052/10061/10047/1000.0779.96%ADMA vs AGIO
ALMS
Alumis Inc.
20/100—13/10020/1000.65137.60%ADMA vs ALMS
AMLX
Amylyx Pharmaceuticals, Inc.
78/100—90/10048/1001.3587.03%ADMA vs AMLX
ANAB
AnaptysBio, Inc.
56/10074/10036/10046/1000.7864.84%ADMA vs ANAB
Pairwise Compare links: AGIO · ALMS · AMLX · ANABADMA vs AGIOADMA vs ALMSADMA vs AMLXADMA vs ANABCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ADMA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ADMA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
17.32
As of Nov 13, 2026
Revenue growth
5.12%
Gross margin
68.53%
Current debt / equity
0.46
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$141.1M
Quarter net income
$49.88M
Quarter free cash flow
$15.37M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
71.04
MACD
0.78

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
56/100
Beta
-0.09
Annual volatility
58.93%
Max drawdown
-62.71%

ADMA Stock FAQ

What is ADMA stock price today?

ADMA Biologics, Inc.'s current stock price is $13.68. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ADMA bullish or bearish right now?

ADMA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ADMA's market cap?

ADMA's market cap is $3.06B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ADMA's current P/E ratio?

ADMA's current P/E ratio is 17.32 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ADMA's RSI?

ADMA's 14-day RSI is 71.04 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ADMA above its 50-day and 200-day moving averages?

ADMA is 29.36% from its 50-day SMA and 27.55% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ADMA's next earnings date?

ADMA's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ADMA pay a dividend?

ADMA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.